nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—lung cancer	0.145	1	CbGaD
Nefazodone—CYP3A5—Gefitinib—lung cancer	0.0286	0.0523	CbGbCtD
Nefazodone—CYP3A5—Teniposide—lung cancer	0.0277	0.0507	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.0206	0.0377	CbGbCtD
Nefazodone—CYP3A7—Paclitaxel—lung cancer	0.0206	0.0377	CbGbCtD
Nefazodone—CYP3A7—Irinotecan—lung cancer	0.0204	0.0372	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.0204	0.0372	CbGbCtD
Nefazodone—ABCB1—Topotecan—lung cancer	0.0204	0.0372	CbGbCtD
Nefazodone—ABCB1—Gefitinib—lung cancer	0.0186	0.034	CbGbCtD
Nefazodone—CYP2D6—Gefitinib—lung cancer	0.0175	0.032	CbGbCtD
Nefazodone—CYP3A5—Crizotinib—lung cancer	0.0175	0.032	CbGbCtD
Nefazodone—CYP3A5—Erlotinib—lung cancer	0.0169	0.0309	CbGbCtD
Nefazodone—CYP3A5—Paclitaxel—lung cancer	0.0155	0.0283	CbGbCtD
Nefazodone—CYP3A5—Irinotecan—lung cancer	0.0153	0.0279	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—lung cancer	0.0149	0.0273	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.0149	0.0273	CbGbCtD
Nefazodone—ABCB1—Vinorelbine—lung cancer	0.0143	0.0262	CbGbCtD
Nefazodone—CYP2D6—Vinorelbine—lung cancer	0.0135	0.0247	CbGbCtD
Nefazodone—CYP3A5—Etoposide—lung cancer	0.0122	0.0224	CbGbCtD
Nefazodone—CYP3A4—Topotecan—lung cancer	0.0122	0.0223	CbGbCtD
Nefazodone—ABCB1—Crizotinib—lung cancer	0.0114	0.0208	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—lung cancer	0.0112	0.0204	CbGbCtD
Nefazodone—CYP3A4—Gefitinib—lung cancer	0.0112	0.0204	CbGbCtD
Nefazodone—ABCB1—Gemcitabine—lung cancer	0.0112	0.0204	CbGbCtD
Nefazodone—ABCB1—Erlotinib—lung cancer	0.011	0.0201	CbGbCtD
Nefazodone—CYP3A4—Teniposide—lung cancer	0.0108	0.0198	CbGbCtD
Nefazodone—CYP2D6—Erlotinib—lung cancer	0.0104	0.0189	CbGbCtD
Nefazodone—ABCB1—Paclitaxel—lung cancer	0.0101	0.0184	CbGbCtD
Nefazodone—ABCB1—Irinotecan—lung cancer	0.00994	0.0182	CbGbCtD
Nefazodone—ABCB1—Vinblastine—lung cancer	0.00884	0.0161	CbGbCtD
Nefazodone—CYP3A4—Vinorelbine—lung cancer	0.0086	0.0157	CbGbCtD
Nefazodone—CYP2D6—Vinblastine—lung cancer	0.00833	0.0152	CbGbCtD
Nefazodone—ABCB1—Cisplatin—lung cancer	0.00811	0.0148	CbGbCtD
Nefazodone—ABCB1—Etoposide—lung cancer	0.00796	0.0145	CbGbCtD
Nefazodone—ABCB1—Docetaxel—lung cancer	0.00729	0.0133	CbGbCtD
Nefazodone—CYP3A4—Crizotinib—lung cancer	0.00684	0.0125	CbGbCtD
Nefazodone—CYP3A4—Erlotinib—lung cancer	0.0066	0.012	CbGbCtD
Nefazodone—CYP3A4—Paclitaxel—lung cancer	0.00604	0.011	CbGbCtD
Nefazodone—CYP3A4—Irinotecan—lung cancer	0.00596	0.0109	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—lung cancer	0.00543	0.00992	CbGbCtD
Nefazodone—CYP3A4—Vinblastine—lung cancer	0.0053	0.00967	CbGbCtD
Nefazodone—ABCB1—Methotrexate—lung cancer	0.00526	0.00961	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—lung cancer	0.00512	0.00935	CbGbCtD
Nefazodone—CYP3A4—Etoposide—lung cancer	0.00477	0.00872	CbGbCtD
Nefazodone—HTR2A—phrenic nerve—lung cancer	0.00449	0.371	CbGeAlD
Nefazodone—CYP3A4—Docetaxel—lung cancer	0.00437	0.00797	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—lung cancer	0.00325	0.00594	CbGbCtD
Nefazodone—HTR2A—pulmonary artery—lung cancer	0.00163	0.135	CbGeAlD
Nefazodone—SLC6A3—respiratory system—lung cancer	0.000565	0.0467	CbGeAlD
Nefazodone—SLC6A4—respiratory system—lung cancer	0.000518	0.0428	CbGeAlD
Nefazodone—SLC6A2—respiratory system—lung cancer	0.000456	0.0377	CbGeAlD
Nefazodone—ADRA1A—epithelium—lung cancer	0.000354	0.0293	CbGeAlD
Nefazodone—CYP3A5—respiratory system—lung cancer	0.000338	0.0279	CbGeAlD
Nefazodone—SLC6A3—lung—lung cancer	0.0003	0.0248	CbGeAlD
Nefazodone—SLC6A4—lung—lung cancer	0.000275	0.0227	CbGeAlD
Nefazodone—HTR2A—respiratory system—lung cancer	0.000274	0.0226	CbGeAlD
Nefazodone—ADRA2A—bronchus—lung cancer	0.000265	0.0219	CbGeAlD
Nefazodone—SLC6A2—lung—lung cancer	0.000242	0.02	CbGeAlD
Nefazodone—ADRA2A—trachea—lung cancer	0.000238	0.0197	CbGeAlD
Nefazodone—HTR2A—epithelium—lung cancer	0.000229	0.0189	CbGeAlD
Nefazodone—ADRA2A—cardiac atrium—lung cancer	0.000224	0.0185	CbGeAlD
Nefazodone—HTR2A—trachea—lung cancer	0.000203	0.0167	CbGeAlD
Nefazodone—ABCB1—respiratory system—lung cancer	0.00018	0.0148	CbGeAlD
Nefazodone—CYP3A5—lung—lung cancer	0.000179	0.0148	CbGeAlD
Nefazodone—ADRA2A—lung—lung cancer	0.000171	0.0141	CbGeAlD
Nefazodone—SLC6A2—lymph node—lung cancer	0.000166	0.0137	CbGeAlD
Nefazodone—ABCB1—epithelium—lung cancer	0.00015	0.0124	CbGeAlD
Nefazodone—HTR2A—lung—lung cancer	0.000146	0.012	CbGeAlD
Nefazodone—ABCB1—trachea—lung cancer	0.000133	0.011	CbGeAlD
Nefazodone—ADRA2A—lymph node—lung cancer	0.000117	0.00967	CbGeAlD
Nefazodone—Fluphenazine—CYP2E1—lung cancer	0.000116	0.195	CrCbGaD
Nefazodone—ABCB1—bone marrow—lung cancer	0.000105	0.00869	CbGeAlD
Nefazodone—Domperidone—ABCB1—lung cancer	9.73e-05	0.164	CrCbGaD
Nefazodone—ABCB1—lung—lung cancer	9.53e-05	0.00788	CbGeAlD
Nefazodone—Musculoskeletal discomfort—Paclitaxel—lung cancer	8.48e-05	0.000415	CcSEcCtD
Nefazodone—Dyspnoea—Etoposide—lung cancer	8.47e-05	0.000414	CcSEcCtD
Nefazodone—Somnolence—Etoposide—lung cancer	8.44e-05	0.000413	CcSEcCtD
Nefazodone—Cough—Docetaxel—lung cancer	8.44e-05	0.000413	CcSEcCtD
Nefazodone—Angina pectoris—Doxorubicin—lung cancer	8.44e-05	0.000412	CcSEcCtD
Nefazodone—Insomnia—Paclitaxel—lung cancer	8.42e-05	0.000412	CcSEcCtD
Nefazodone—Epistaxis—Methotrexate—lung cancer	8.41e-05	0.000411	CcSEcCtD
Nefazodone—Hypersensitivity—Irinotecan—lung cancer	8.41e-05	0.000411	CcSEcCtD
Nefazodone—Convulsion—Docetaxel—lung cancer	8.38e-05	0.00041	CcSEcCtD
Nefazodone—Paraesthesia—Paclitaxel—lung cancer	8.36e-05	0.000409	CcSEcCtD
Nefazodone—Hypertension—Docetaxel—lung cancer	8.35e-05	0.000408	CcSEcCtD
Nefazodone—Bronchitis—Doxorubicin—lung cancer	8.33e-05	0.000407	CcSEcCtD
Nefazodone—Dyspnoea—Paclitaxel—lung cancer	8.3e-05	0.000406	CcSEcCtD
Nefazodone—Somnolence—Paclitaxel—lung cancer	8.28e-05	0.000405	CcSEcCtD
Nefazodone—Decreased appetite—Etoposide—lung cancer	8.25e-05	0.000404	CcSEcCtD
Nefazodone—Arthralgia—Docetaxel—lung cancer	8.23e-05	0.000402	CcSEcCtD
Nefazodone—Chest pain—Docetaxel—lung cancer	8.23e-05	0.000402	CcSEcCtD
Nefazodone—Myalgia—Docetaxel—lung cancer	8.23e-05	0.000402	CcSEcCtD
Nefazodone—Nausea—Vinorelbine—lung cancer	8.22e-05	0.000402	CcSEcCtD
Nefazodone—Dyspepsia—Paclitaxel—lung cancer	8.2e-05	0.000401	CcSEcCtD
Nefazodone—Body temperature increased—Cisplatin—lung cancer	8.19e-05	0.000401	CcSEcCtD
Nefazodone—Asthenia—Irinotecan—lung cancer	8.19e-05	0.0004	CcSEcCtD
Nefazodone—Pain—Etoposide—lung cancer	8.12e-05	0.000397	CcSEcCtD
Nefazodone—Constipation—Etoposide—lung cancer	8.12e-05	0.000397	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—lung cancer	8.1e-05	0.000396	CcSEcCtD
Nefazodone—Decreased appetite—Paclitaxel—lung cancer	8.09e-05	0.000396	CcSEcCtD
Nefazodone—Dry mouth—Docetaxel—lung cancer	8.05e-05	0.000394	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—lung cancer	8.05e-05	0.000393	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—lung cancer	8.01e-05	0.000391	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—lung cancer	8.01e-05	0.000391	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—lung cancer	8e-05	0.000391	CcSEcCtD
Nefazodone—Asthenia—Gemcitabine—lung cancer	7.98e-05	0.00039	CcSEcCtD
Nefazodone—Constipation—Paclitaxel—lung cancer	7.96e-05	0.000389	CcSEcCtD
Nefazodone—Pain—Paclitaxel—lung cancer	7.96e-05	0.000389	CcSEcCtD
Nefazodone—Confusional state—Docetaxel—lung cancer	7.96e-05	0.000389	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—lung cancer	7.95e-05	0.000388	CcSEcCtD
Nefazodone—Photosensitivity reaction—Doxorubicin—lung cancer	7.9e-05	0.000386	CcSEcCtD
Nefazodone—Anaphylactic shock—Docetaxel—lung cancer	7.89e-05	0.000386	CcSEcCtD
Nefazodone—Oedema—Docetaxel—lung cancer	7.89e-05	0.000386	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—lung cancer	7.88e-05	0.000385	CcSEcCtD
Nefazodone—Pruritus—Gemcitabine—lung cancer	7.87e-05	0.000385	CcSEcCtD
Nefazodone—Infection—Docetaxel—lung cancer	7.84e-05	0.000383	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—lung cancer	7.84e-05	0.000383	CcSEcCtD
Nefazodone—Feeling abnormal—Etoposide—lung cancer	7.82e-05	0.000383	CcSEcCtD
Nefazodone—Diarrhoea—Irinotecan—lung cancer	7.81e-05	0.000382	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—lung cancer	7.77e-05	0.00038	CcSEcCtD
Nefazodone—Gastrointestinal pain—Etoposide—lung cancer	7.76e-05	0.00038	CcSEcCtD
Nefazodone—Shock—Docetaxel—lung cancer	7.76e-05	0.00038	CcSEcCtD
Nefazodone—Thrombocytopenia—Docetaxel—lung cancer	7.73e-05	0.000378	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—lung cancer	7.71e-05	0.000377	CcSEcCtD
Nefazodone—Tachycardia—Docetaxel—lung cancer	7.7e-05	0.000377	CcSEcCtD
Nefazodone—Feeling abnormal—Paclitaxel—lung cancer	7.67e-05	0.000375	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—lung cancer	7.66e-05	0.000374	CcSEcCtD
Nefazodone—Hypersensitivity—Cisplatin—lung cancer	7.64e-05	0.000373	CcSEcCtD
Nefazodone—Gastrointestinal pain—Paclitaxel—lung cancer	7.61e-05	0.000372	CcSEcCtD
Nefazodone—Diarrhoea—Gemcitabine—lung cancer	7.61e-05	0.000372	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—lung cancer	7.57e-05	0.00037	CcSEcCtD
Nefazodone—Dizziness—Irinotecan—lung cancer	7.55e-05	0.000369	CcSEcCtD
Nefazodone—Urticaria—Etoposide—lung cancer	7.54e-05	0.000369	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—lung cancer	7.53e-05	0.000368	CcSEcCtD
Nefazodone—Anorexia—Docetaxel—lung cancer	7.52e-05	0.000368	CcSEcCtD
Nefazodone—Aripiprazole—ABCB1—lung cancer	7.51e-05	0.127	CrCbGaD
Nefazodone—Abdominal pain—Etoposide—lung cancer	7.51e-05	0.000367	CcSEcCtD
Nefazodone—Body temperature increased—Etoposide—lung cancer	7.51e-05	0.000367	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—lung cancer	7.51e-05	0.000367	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—lung cancer	7.51e-05	0.000367	CcSEcCtD
Nefazodone—Trazodone—ABCB1—lung cancer	7.48e-05	0.126	CrCbGaD
Nefazodone—Thioproperazine—ALB—lung cancer	7.46e-05	0.126	CrCbGaD
Nefazodone—Tinnitus—Methotrexate—lung cancer	7.46e-05	0.000365	CcSEcCtD
Nefazodone—Asthenia—Cisplatin—lung cancer	7.44e-05	0.000364	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—lung cancer	7.4e-05	0.000362	CcSEcCtD
Nefazodone—Urticaria—Paclitaxel—lung cancer	7.4e-05	0.000362	CcSEcCtD
Nefazodone—Hypotension—Docetaxel—lung cancer	7.37e-05	0.000361	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—lung cancer	7.36e-05	0.00036	CcSEcCtD
Nefazodone—Body temperature increased—Paclitaxel—lung cancer	7.36e-05	0.00036	CcSEcCtD
Nefazodone—Abdominal pain—Paclitaxel—lung cancer	7.36e-05	0.00036	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—lung cancer	7.28e-05	0.000356	CcSEcCtD
Nefazodone—Vomiting—Irinotecan—lung cancer	7.26e-05	0.000355	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—lung cancer	7.24e-05	0.000354	CcSEcCtD
Nefazodone—Rash—Irinotecan—lung cancer	7.2e-05	0.000352	CcSEcCtD
Nefazodone—Dermatitis—Irinotecan—lung cancer	7.19e-05	0.000352	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Docetaxel—lung cancer	7.19e-05	0.000352	CcSEcCtD
Nefazodone—Chills—Methotrexate—lung cancer	7.18e-05	0.000351	CcSEcCtD
Nefazodone—Headache—Irinotecan—lung cancer	7.15e-05	0.00035	CcSEcCtD
Nefazodone—Insomnia—Docetaxel—lung cancer	7.14e-05	0.000349	CcSEcCtD
Nefazodone—Diarrhoea—Cisplatin—lung cancer	7.09e-05	0.000347	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—lung cancer	7.09e-05	0.000346	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—lung cancer	7.07e-05	0.000346	CcSEcCtD
Nefazodone—Vomiting—Gemcitabine—lung cancer	7.07e-05	0.000346	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—lung cancer	7.06e-05	0.000345	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—lung cancer	7.04e-05	0.000344	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—lung cancer	7.02e-05	0.000343	CcSEcCtD
Nefazodone—Rash—Gemcitabine—lung cancer	7.01e-05	0.000343	CcSEcCtD
Nefazodone—Dermatitis—Gemcitabine—lung cancer	7e-05	0.000342	CcSEcCtD
Nefazodone—Hypersensitivity—Etoposide—lung cancer	7e-05	0.000342	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—lung cancer	6.97e-05	0.000341	CcSEcCtD
Nefazodone—Headache—Gemcitabine—lung cancer	6.97e-05	0.000341	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—lung cancer	6.95e-05	0.00034	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—lung cancer	6.95e-05	0.00034	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—lung cancer	6.93e-05	0.000339	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—lung cancer	6.93e-05	0.000339	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—lung cancer	6.9e-05	0.000337	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—lung cancer	6.88e-05	0.000336	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—lung cancer	6.86e-05	0.000335	CcSEcCtD
Nefazodone—Hypersensitivity—Paclitaxel—lung cancer	6.86e-05	0.000335	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—lung cancer	6.83e-05	0.000334	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—lung cancer	6.82e-05	0.000334	CcSEcCtD
Nefazodone—Asthenia—Etoposide—lung cancer	6.81e-05	0.000333	CcSEcCtD
Nefazodone—Nausea—Irinotecan—lung cancer	6.78e-05	0.000332	CcSEcCtD
Nefazodone—Constipation—Docetaxel—lung cancer	6.75e-05	0.00033	CcSEcCtD
Nefazodone—Pain—Docetaxel—lung cancer	6.75e-05	0.00033	CcSEcCtD
Nefazodone—Back pain—Methotrexate—lung cancer	6.74e-05	0.00033	CcSEcCtD
Nefazodone—Pruritus—Etoposide—lung cancer	6.72e-05	0.000328	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—lung cancer	6.68e-05	0.000327	CcSEcCtD
Nefazodone—Asthenia—Paclitaxel—lung cancer	6.68e-05	0.000327	CcSEcCtD
Nefazodone—Nausea—Gemcitabine—lung cancer	6.6e-05	0.000323	CcSEcCtD
Nefazodone—Vomiting—Cisplatin—lung cancer	6.59e-05	0.000322	CcSEcCtD
Nefazodone—Pruritus—Paclitaxel—lung cancer	6.59e-05	0.000322	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—lung cancer	6.57e-05	0.000321	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—lung cancer	6.55e-05	0.00032	CcSEcCtD
Nefazodone—Rash—Cisplatin—lung cancer	6.53e-05	0.00032	CcSEcCtD
Nefazodone—Dermatitis—Cisplatin—lung cancer	6.53e-05	0.000319	CcSEcCtD
Nefazodone—ABCB1—lymph node—lung cancer	6.52e-05	0.00539	CbGeAlD
Nefazodone—Feeling abnormal—Docetaxel—lung cancer	6.5e-05	0.000318	CcSEcCtD
Nefazodone—Diarrhoea—Etoposide—lung cancer	6.5e-05	0.000318	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—lung cancer	6.47e-05	0.000316	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—lung cancer	6.46e-05	0.000316	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—lung cancer	6.45e-05	0.000315	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—lung cancer	6.44e-05	0.000315	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—lung cancer	6.43e-05	0.000315	CcSEcCtD
Nefazodone—Diarrhoea—Paclitaxel—lung cancer	6.37e-05	0.000311	CcSEcCtD
Nefazodone—Malaise—Methotrexate—lung cancer	6.28e-05	0.000307	CcSEcCtD
Nefazodone—Dizziness—Etoposide—lung cancer	6.28e-05	0.000307	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—lung cancer	6.26e-05	0.000306	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—lung cancer	6.24e-05	0.000305	CcSEcCtD
Nefazodone—Body temperature increased—Docetaxel—lung cancer	6.24e-05	0.000305	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—lung cancer	6.24e-05	0.000305	CcSEcCtD
Nefazodone—Chills—Doxorubicin—lung cancer	6.22e-05	0.000304	CcSEcCtD
Nefazodone—Dizziness—Paclitaxel—lung cancer	6.16e-05	0.000301	CcSEcCtD
Nefazodone—Nausea—Cisplatin—lung cancer	6.16e-05	0.000301	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—lung cancer	6.13e-05	0.000299	CcSEcCtD
Nefazodone—Cough—Methotrexate—lung cancer	6.08e-05	0.000297	CcSEcCtD
Nefazodone—Fluphenazine—ABCB1—lung cancer	6.06e-05	0.102	CrCbGaD
Nefazodone—Convulsion—Methotrexate—lung cancer	6.04e-05	0.000295	CcSEcCtD
Nefazodone—Vomiting—Etoposide—lung cancer	6.04e-05	0.000295	CcSEcCtD
Nefazodone—Rash—Etoposide—lung cancer	5.99e-05	0.000293	CcSEcCtD
Nefazodone—Dermatitis—Etoposide—lung cancer	5.98e-05	0.000292	CcSEcCtD
Nefazodone—Headache—Etoposide—lung cancer	5.95e-05	0.000291	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—lung cancer	5.95e-05	0.000291	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—lung cancer	5.93e-05	0.00029	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—lung cancer	5.93e-05	0.00029	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—lung cancer	5.93e-05	0.00029	CcSEcCtD
Nefazodone—Vomiting—Paclitaxel—lung cancer	5.92e-05	0.000289	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—lung cancer	5.91e-05	0.000289	CcSEcCtD
Nefazodone—Rash—Paclitaxel—lung cancer	5.87e-05	0.000287	CcSEcCtD
Nefazodone—Dermatitis—Paclitaxel—lung cancer	5.86e-05	0.000287	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—lung cancer	5.86e-05	0.000287	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—lung cancer	5.84e-05	0.000285	CcSEcCtD
Nefazodone—Headache—Paclitaxel—lung cancer	5.83e-05	0.000285	CcSEcCtD
Nefazodone—Hypersensitivity—Docetaxel—lung cancer	5.81e-05	0.000284	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—lung cancer	5.8e-05	0.000284	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—lung cancer	5.73e-05	0.00028	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—lung cancer	5.69e-05	0.000278	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—lung cancer	5.69e-05	0.000278	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—lung cancer	5.66e-05	0.000277	CcSEcCtD
Nefazodone—Infection—Methotrexate—lung cancer	5.65e-05	0.000276	CcSEcCtD
Nefazodone—Nausea—Etoposide—lung cancer	5.64e-05	0.000276	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—lung cancer	5.6e-05	0.000274	CcSEcCtD
Nefazodone—Pruritus—Docetaxel—lung cancer	5.58e-05	0.000273	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—lung cancer	5.58e-05	0.000273	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—lung cancer	5.57e-05	0.000272	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—lung cancer	5.55e-05	0.000271	CcSEcCtD
Nefazodone—Nausea—Paclitaxel—lung cancer	5.53e-05	0.00027	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—lung cancer	5.5e-05	0.000269	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—lung cancer	5.44e-05	0.000266	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—lung cancer	5.42e-05	0.000265	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—lung cancer	5.42e-05	0.000265	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—lung cancer	5.41e-05	0.000265	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—lung cancer	5.4e-05	0.000264	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—lung cancer	5.4e-05	0.000264	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—lung cancer	5.33e-05	0.000261	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—lung cancer	5.31e-05	0.00026	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—lung cancer	5.3e-05	0.000259	CcSEcCtD
Nefazodone—Cough—Doxorubicin—lung cancer	5.27e-05	0.000257	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—lung cancer	5.23e-05	0.000256	CcSEcCtD
Nefazodone—Dizziness—Docetaxel—lung cancer	5.22e-05	0.000255	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—lung cancer	5.21e-05	0.000255	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—lung cancer	5.18e-05	0.000253	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—lung cancer	5.14e-05	0.000252	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—lung cancer	5.14e-05	0.000251	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—lung cancer	5.14e-05	0.000251	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—lung cancer	5.14e-05	0.000251	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—lung cancer	5.12e-05	0.00025	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—lung cancer	5.11e-05	0.00025	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—lung cancer	5.08e-05	0.000248	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—lung cancer	5.07e-05	0.000248	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—lung cancer	5.06e-05	0.000247	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—lung cancer	5.02e-05	0.000246	CcSEcCtD
Nefazodone—Vomiting—Docetaxel—lung cancer	5.02e-05	0.000245	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—lung cancer	5.01e-05	0.000245	CcSEcCtD
Nefazodone—Rash—Docetaxel—lung cancer	4.98e-05	0.000243	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—lung cancer	4.97e-05	0.000243	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—lung cancer	4.97e-05	0.000243	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—lung cancer	4.94e-05	0.000242	CcSEcCtD
Nefazodone—Headache—Docetaxel—lung cancer	4.94e-05	0.000242	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—lung cancer	4.92e-05	0.000241	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—lung cancer	4.92e-05	0.000241	CcSEcCtD
Nefazodone—Infection—Doxorubicin—lung cancer	4.89e-05	0.000239	CcSEcCtD
Nefazodone—Pain—Methotrexate—lung cancer	4.86e-05	0.000238	CcSEcCtD
Nefazodone—Shock—Doxorubicin—lung cancer	4.85e-05	0.000237	CcSEcCtD
Nefazodone—Trifluoperazine—ABCB1—lung cancer	4.84e-05	0.0816	CrCbGaD
Nefazodone—Thrombocytopenia—Doxorubicin—lung cancer	4.82e-05	0.000236	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—lung cancer	4.81e-05	0.000235	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—lung cancer	4.76e-05	0.000233	CcSEcCtD
Nefazodone—Quetiapine—ABCB1—lung cancer	4.7e-05	0.0791	CrCbGaD
Nefazodone—Anorexia—Doxorubicin—lung cancer	4.69e-05	0.00023	CcSEcCtD
Nefazodone—Nausea—Docetaxel—lung cancer	4.69e-05	0.000229	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—lung cancer	4.69e-05	0.000229	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—lung cancer	4.65e-05	0.000227	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—lung cancer	4.6e-05	0.000225	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—lung cancer	4.52e-05	0.000221	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—lung cancer	4.5e-05	0.00022	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—lung cancer	4.5e-05	0.00022	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—lung cancer	4.49e-05	0.000219	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—lung cancer	4.45e-05	0.000218	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—lung cancer	4.42e-05	0.000216	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—lung cancer	4.39e-05	0.000215	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—lung cancer	4.38e-05	0.000214	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—lung cancer	4.34e-05	0.000212	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—lung cancer	4.28e-05	0.000209	CcSEcCtD
Nefazodone—Pain—Doxorubicin—lung cancer	4.21e-05	0.000206	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—lung cancer	4.21e-05	0.000206	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—lung cancer	4.19e-05	0.000205	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—lung cancer	4.08e-05	0.0002	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—lung cancer	4.06e-05	0.000198	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—lung cancer	4.03e-05	0.000197	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—lung cancer	4.02e-05	0.000197	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—lung cancer	3.91e-05	0.000191	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—lung cancer	3.89e-05	0.00019	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—lung cancer	3.89e-05	0.00019	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—lung cancer	3.89e-05	0.00019	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—lung cancer	3.76e-05	0.000184	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—lung cancer	3.63e-05	0.000177	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—lung cancer	3.62e-05	0.000177	CcSEcCtD
Nefazodone—Rash—Methotrexate—lung cancer	3.59e-05	0.000175	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—lung cancer	3.58e-05	0.000175	CcSEcCtD
Nefazodone—Headache—Methotrexate—lung cancer	3.56e-05	0.000174	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—lung cancer	3.53e-05	0.000173	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—lung cancer	3.48e-05	0.00017	CcSEcCtD
Nefazodone—Nausea—Methotrexate—lung cancer	3.38e-05	0.000165	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—lung cancer	3.37e-05	0.000165	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—lung cancer	3.26e-05	0.000159	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—lung cancer	3.13e-05	0.000153	CcSEcCtD
Nefazodone—Rash—Doxorubicin—lung cancer	3.11e-05	0.000152	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—lung cancer	3.1e-05	0.000152	CcSEcCtD
Nefazodone—Headache—Doxorubicin—lung cancer	3.09e-05	0.000151	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—lung cancer	2.93e-05	0.000143	CcSEcCtD
Nefazodone—ADRA1B—Signaling Pathways—RAF1—lung cancer	4.39e-06	4.89e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	4.36e-06	4.86e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—lung cancer	4.36e-06	4.86e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—lung cancer	4.34e-06	4.83e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BRAF—lung cancer	4.33e-06	4.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	4.32e-06	4.82e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—lung cancer	4.32e-06	4.81e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—lung cancer	4.3e-06	4.79e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRAS—lung cancer	4.29e-06	4.78e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6R—lung cancer	4.28e-06	4.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CB—lung cancer	4.28e-06	4.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MTOR—lung cancer	4.28e-06	4.77e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CREBBP—lung cancer	4.28e-06	4.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—lung cancer	4.27e-06	4.76e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRAS—lung cancer	4.27e-06	4.76e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CB—lung cancer	4.23e-06	4.71e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—lung cancer	4.2e-06	4.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—lung cancer	4.19e-06	4.67e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOA1—lung cancer	4.18e-06	4.65e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2E1—lung cancer	4.17e-06	4.65e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—lung cancer	4.17e-06	4.65e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—lung cancer	4.15e-06	4.63e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—lung cancer	4.13e-06	4.61e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—lung cancer	4.13e-06	4.6e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NQO1—lung cancer	4.13e-06	4.6e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—lung cancer	4.11e-06	4.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—lung cancer	4.11e-06	4.58e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—lung cancer	4.11e-06	4.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—lung cancer	4.11e-06	4.58e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—lung cancer	4.09e-06	4.56e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—lung cancer	4.09e-06	4.55e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	4.08e-06	4.55e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	4.05e-06	4.52e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—lung cancer	4.02e-06	4.49e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JUN—lung cancer	4.02e-06	4.48e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	4.02e-06	4.47e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	4.01e-06	4.47e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—lung cancer	4e-06	4.46e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JUN—lung cancer	4e-06	4.45e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MDM2—lung cancer	3.99e-06	4.45e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RAF1—lung cancer	3.98e-06	4.43e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	3.97e-06	4.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—lung cancer	3.97e-06	4.42e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—lung cancer	3.94e-06	4.39e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOA1—lung cancer	3.94e-06	4.39e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—lung cancer	3.94e-06	4.39e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—lung cancer	3.93e-06	4.38e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	3.92e-06	4.37e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—lung cancer	3.91e-06	4.36e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MDM2—lung cancer	3.91e-06	4.36e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—lung cancer	3.91e-06	4.35e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RAF1—lung cancer	3.89e-06	4.34e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1A—lung cancer	3.89e-06	4.34e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—lung cancer	3.89e-06	4.33e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—lung cancer	3.88e-06	4.33e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CB—lung cancer	3.88e-06	4.33e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MTOR—lung cancer	3.88e-06	4.33e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1A—lung cancer	3.87e-06	4.32e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CB—lung cancer	3.87e-06	4.32e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—lung cancer	3.86e-06	4.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—lung cancer	3.85e-06	4.29e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—lung cancer	3.84e-06	4.28e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—lung cancer	3.83e-06	4.27e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JUN—lung cancer	3.82e-06	4.26e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—lung cancer	3.81e-06	4.25e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MTOR—lung cancer	3.8e-06	4.24e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	3.8e-06	4.24e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—lung cancer	3.79e-06	4.22e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—lung cancer	3.77e-06	4.2e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—lung cancer	3.73e-06	4.16e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—lung cancer	3.72e-06	4.15e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—STK11—lung cancer	3.72e-06	4.15e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—lung cancer	3.71e-06	4.13e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	3.71e-06	4.13e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EP300—lung cancer	3.7e-06	4.13e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—lung cancer	3.7e-06	4.12e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EP300—lung cancer	3.69e-06	4.11e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—lung cancer	3.65e-06	4.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—lung cancer	3.65e-06	4.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	3.65e-06	4.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MDM2—lung cancer	3.63e-06	4.05e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—lung cancer	3.63e-06	4.05e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—POMC—lung cancer	3.63e-06	4.05e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RAF1—lung cancer	3.62e-06	4.03e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—lung cancer	3.61e-06	4.02e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—lung cancer	3.61e-06	4.02e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SRC—lung cancer	3.6e-06	4.01e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—lung cancer	3.59e-06	4e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SRC—lung cancer	3.58e-06	3.99e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—lung cancer	3.58e-06	3.99e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—lung cancer	3.57e-06	3.98e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—lung cancer	3.57e-06	3.97e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—lung cancer	3.55e-06	3.95e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CREBBP—lung cancer	3.54e-06	3.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	3.53e-06	3.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MTOR—lung cancer	3.53e-06	3.94e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	3.53e-06	3.93e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EP300—lung cancer	3.53e-06	3.93e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—lung cancer	3.51e-06	3.91e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—lung cancer	3.5e-06	3.9e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—lung cancer	3.49e-06	3.89e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—lung cancer	3.49e-06	3.89e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—EP300—lung cancer	3.48e-06	3.88e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—lung cancer	3.48e-06	3.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—lung cancer	3.47e-06	3.87e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—lung cancer	3.47e-06	3.87e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JUN—lung cancer	3.47e-06	3.87e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NRAS—lung cancer	3.47e-06	3.86e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—lung cancer	3.46e-06	3.85e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NRAS—lung cancer	3.45e-06	3.84e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—lung cancer	3.44e-06	3.84e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SRC—lung cancer	3.43e-06	3.82e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—POMC—lung cancer	3.42e-06	3.81e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—lung cancer	3.4e-06	3.79e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JUN—lung cancer	3.4e-06	3.79e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—lung cancer	3.4e-06	3.78e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—lung cancer	3.38e-06	3.76e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—lung cancer	3.37e-06	3.76e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1A—lung cancer	3.36e-06	3.75e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—lung cancer	3.36e-06	3.74e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CD—lung cancer	3.35e-06	3.74e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAT—lung cancer	3.35e-06	3.73e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—lung cancer	3.35e-06	3.73e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—lung cancer	3.34e-06	3.72e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CREBBP—lung cancer	3.33e-06	3.71e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK3—lung cancer	3.32e-06	3.7e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—lung cancer	3.31e-06	3.69e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—lung cancer	3.31e-06	3.69e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—lung cancer	3.31e-06	3.68e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK3—lung cancer	3.3e-06	3.68e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NRAS—lung cancer	3.3e-06	3.68e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	3.29e-06	3.67e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—lung cancer	3.29e-06	3.66e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	3.28e-06	3.66e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—lung cancer	3.27e-06	3.65e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—lung cancer	3.27e-06	3.64e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—lung cancer	3.26e-06	3.63e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—lung cancer	3.25e-06	3.62e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—lung cancer	3.24e-06	3.62e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—lung cancer	3.23e-06	3.6e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—lung cancer	3.23e-06	3.6e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—lung cancer	3.21e-06	3.58e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—lung cancer	3.21e-06	3.57e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMS—lung cancer	3.2e-06	3.57e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EP300—lung cancer	3.2e-06	3.57e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—EP300—lung cancer	3.19e-06	3.56e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—lung cancer	3.16e-06	3.53e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—lung cancer	3.16e-06	3.53e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK3—lung cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CD—lung cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—lung cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JUN—lung cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—lung cancer	3.14e-06	3.5e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EP300—lung cancer	3.13e-06	3.49e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—lung cancer	3.12e-06	3.48e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SRC—lung cancer	3.11e-06	3.47e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—lung cancer	3.07e-06	3.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—lung cancer	3.07e-06	3.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	3.06e-06	3.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—lung cancer	3.05e-06	3.4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SRC—lung cancer	3.05e-06	3.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—lung cancer	3.03e-06	3.38e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—lung cancer	3.01e-06	3.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—lung cancer	3e-06	3.34e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1A1—lung cancer	3e-06	3.34e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NRAS—lung cancer	2.99e-06	3.34e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—lung cancer	2.98e-06	3.32e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—lung cancer	2.98e-06	3.32e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ERCC2—lung cancer	2.97e-06	3.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—lung cancer	2.97e-06	3.31e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—lung cancer	2.97e-06	3.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—lung cancer	2.94e-06	3.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NRAS—lung cancer	2.93e-06	3.27e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CB—lung cancer	2.92e-06	3.26e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EP300—lung cancer	2.91e-06	3.24e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—lung cancer	2.9e-06	3.23e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK3—lung cancer	2.87e-06	3.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—lung cancer	2.84e-06	3.17e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SRC—lung cancer	2.83e-06	3.16e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK3—lung cancer	2.81e-06	3.13e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—lung cancer	2.79e-06	3.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—lung cancer	2.76e-06	3.07e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CB—lung cancer	2.75e-06	3.07e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—lung cancer	2.74e-06	3.05e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—lung cancer	2.73e-06	3.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—lung cancer	2.73e-06	3.04e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—lung cancer	2.73e-06	3.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—lung cancer	2.73e-06	3.04e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—lung cancer	2.73e-06	3.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NRAS—lung cancer	2.72e-06	3.04e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—lung cancer	2.67e-06	2.98e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—lung cancer	2.67e-06	2.97e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—lung cancer	2.65e-06	2.95e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—lung cancer	2.64e-06	2.94e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	2.61e-06	2.91e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK3—lung cancer	2.61e-06	2.91e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—lung cancer	2.58e-06	2.87e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—lung cancer	2.58e-06	2.87e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOA1—lung cancer	2.57e-06	2.87e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—lung cancer	2.54e-06	2.83e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—lung cancer	2.54e-06	2.83e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—lung cancer	2.52e-06	2.81e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—lung cancer	2.52e-06	2.81e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—lung cancer	2.52e-06	2.81e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—lung cancer	2.52e-06	2.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—lung cancer	2.48e-06	2.77e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—lung cancer	2.43e-06	2.7e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—lung cancer	2.41e-06	2.69e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—lung cancer	2.41e-06	2.69e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—EP300—lung cancer	2.41e-06	2.68e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—lung cancer	2.38e-06	2.65e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—lung cancer	2.37e-06	2.64e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—lung cancer	2.36e-06	2.63e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—lung cancer	2.35e-06	2.62e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—lung cancer	2.34e-06	2.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	2.32e-06	2.58e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—lung cancer	2.31e-06	2.58e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—lung cancer	2.29e-06	2.55e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—EP300—lung cancer	2.27e-06	2.53e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—lung cancer	2.24e-06	2.5e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—lung cancer	2.24e-06	2.49e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—POMC—lung cancer	2.24e-06	2.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—lung cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—lung cancer	2.19e-06	2.44e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CREBBP—lung cancer	2.18e-06	2.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	2.15e-06	2.4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—lung cancer	2.14e-06	2.39e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—lung cancer	2.13e-06	2.38e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—lung cancer	2.1e-06	2.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—lung cancer	2.1e-06	2.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—lung cancer	2.08e-06	2.32e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CD—lung cancer	2.07e-06	2.3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—lung cancer	2.05e-06	2.29e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—lung cancer	2.04e-06	2.27e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.99e-06	2.22e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—lung cancer	1.93e-06	2.16e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—lung cancer	1.93e-06	2.15e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—lung cancer	1.91e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—lung cancer	1.89e-06	2.11e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CB—lung cancer	1.8e-06	2.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—lung cancer	1.78e-06	1.99e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—lung cancer	1.78e-06	1.99e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—lung cancer	1.76e-06	1.96e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—lung cancer	1.68e-06	1.87e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—lung cancer	1.56e-06	1.73e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—EP300—lung cancer	1.48e-06	1.65e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—lung cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—lung cancer	1.37e-06	1.53e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—lung cancer	1.1e-06	1.22e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—lung cancer	8.97e-07	9.99e-06	CbGpPWpGaD
